Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. OBJECTIVE: To evaluate the effect of...

Full description

Saved in:
Bibliographic Details
Published in:JAMA
Main Authors: Rosenstock, Julio, Perkovic, Vlado, Johansen, Odd Erik, Cooper, Mark E., Kahn, Steven E., Marx, Nikolaus, Alexander, John H., Pencina, Michael, Toto, Robert D., Wanner, Christoph, Zinman, Bernard, Woerle, Hans Juergen, Baanstra, David, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, George, Jyothis T., von Eynatten, Maximilian, McGuire, Darren K.
Format: Artigo
Language:Inglês
Published: American Medical Association 2018
Subjects:
Original Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583576/
https://ncbi.nlm.nih.gov/pubmed/30418475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.18269
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items